Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis are seeking to block a major hospital trade group from intervening in ...

The industry could see payment, workforce and insurance coverage changes depending on how the Trump administration weighs in ...

after the regulator rejected their plans to change how they offer 340B discounts. In December, Sanofi and Bristol Myers Squibb followed suit. The discount program designed to keep safety-net ...

The 340B requirement has long been a bone of contention ... Last year, for example, a federal appeals court sided with Sanofi, AstraZeneca, and Novo Nordisk in a dispute claiming that recipients ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

But profits need to come from somewhere. By expanding the federal 340B prescription drug program, the bill increases drug costs for Utah residents and businesses while benefitting the major chain ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 11,687.23 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...

The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

Bernstein analyst Florent Cespedes maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €114.00. The company’s shares closed last Tuesday at $108.11.